Vertex Pharmaceuticals (VRTX) Capital Leases (2016 - 2025)
Historic Capital Leases for Vertex Pharmaceuticals (VRTX) over the last 15 years, with Q1 2025 value amounting to $111.4 million.
- Vertex Pharmaceuticals' Capital Leases fell 6918.4% to $111.4 million in Q1 2025 from the same period last year, while for Mar 2025 it was $111.4 million, marking a year-over-year decrease of 6918.4%. This contributed to the annual value of $112.8 million for FY2024, which is 7000.8% down from last year.
- According to the latest figures from Q1 2025, Vertex Pharmaceuticals' Capital Leases is $111.4 million, which was down 6918.4% from $112.8 million recorded in Q4 2024.
- Vertex Pharmaceuticals' Capital Leases' 5-year high stood at $530.3 million during Q1 2021, with a 5-year trough of $111.4 million in Q1 2025.
- For the 5-year period, Vertex Pharmaceuticals' Capital Leases averaged around $386.1 million, with its median value being $417.6 million (2023).
- Its Capital Leases has fluctuated over the past 5 years, first skyrocketed by 54.74% in 2021, then crashed by 7079.17% in 2024.
- Vertex Pharmaceuticals' Capital Leases (Quarter) stood at $509.8 million in 2021, then dropped by 15.5% to $430.8 million in 2022, then fell by 12.7% to $376.1 million in 2023, then tumbled by 70.01% to $112.8 million in 2024, then fell by 1.24% to $111.4 million in 2025.
- Its Capital Leases was $111.4 million in Q1 2025, compared to $112.8 million in Q4 2024 and $114.0 million in Q3 2024.